Atosiban dosing in preterm labour-made easy for all
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20261654Keywords:
Atosiban, Dose, Preterm, Preterm labour, Prevention of preterm labourAbstract
Preterm labour remains a significant contributor to neonatal morbidity and mortality, particularly in low-resource settings where timely and appropriate interventions may be challenging. Tocolysis plays an important role in delaying delivery and facilitating antenatal corticosteroid administration. Among available agents, Atosiban, a selective oxytocin receptor antagonist, is widely used due to its favorable safety profile and targeted mechanism of action.
References
Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labour. N Engl J Med. 2000;342(5):1503-10.
Dewan B, Navale S, Ganiga R. Atosiban: a comprehensive approach to preterm labour management. Int J Reprod Contracept Obstet Gynecol. 2024;13:3420-31.
Fullerton GM, Black M, Shetty A, Bhattacharya S. Atosiban in the management of preterm labour. Clin Med Insights Womens Health. 2011;4:45-52.
ACOG Practice Bulletin No. 171. Management of preterm labor. Obstet Gynecol. 2016;128:e155-64.
NICE guideline NG25. Preterm labour and birth. 2019.
Papatsonis DN, Flenady V, Cole S, Liley HG. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev. 2005;CD004452.
Lamont RF. The pathophysiology of preterm labour. BJOG. 2003;110(20):7-13.
Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery. Obstet Gynecol. 2012;119:315-28.
Downloads
Published
How to Cite
Issue
Section
